Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
Journal of Korean Medical Science ; : 237-246, 2013.
Artigo em Inglês | WPRIM | ID: wpr-25352

RESUMO

SUV39H1 is a histone 3 lysine 9 (H3K9)-specific methyltransferase that is important for heterochromatin formation and the regulation of gene expression. Chaetocin specifically inhibits SUV39H1, resulted in H3K9 methylation reduction as well as reactivation of silenced genes in cancer cells. Histone deacetylase (HDAC) inhibitors inhibit deacetylases and accumulate high levels of acetylation lead to cell cycle arrest and apoptosis. In this study, we demonstrated that treatment with chaetocin enhanced apoptosis in human leukemia HL60, KG1, Kasumi, K562, and THP1 cells. In addition, chaetocin induced the expression of cyclin-dependent kinase inhibitor 2B (p15), E-cadherin (CDH1) and frizzled family receptor 9 (FZD9) through depletion of SUV39H1 and reduced H3K9 methylation in their promoters. Co-treatment with chaetocin and HDAC inhibitor trichostatin A (TSA) dramatically increased apoptosis and produced greater activation of genes. Furthermore, this combined treatment significantly increased loss of SUV39H1 and reduced histone H3K9 trimethylation responses accompanied by increased acetylation. Importantly, co-treatment with chaetocin and TSA produced potent antileukemic effects in leukemia cells derived from patients. These in vitro findings suggest that combination therapy with SUV39H1 and HDAC inhibitors may be of potential value in the treatment of leukemia.


Assuntos
Adolescente , Adulto , Idoso , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Acetilação/efeitos dos fármacos , Apoptose/efeitos dos fármacos , Caderinas/metabolismo , Linhagem Celular Tumoral , Inibidor de Quinase Dependente de Ciclina p15/metabolismo , Metilação de DNA/efeitos dos fármacos , Inibidores Enzimáticos/uso terapêutico , Receptores Frizzled/metabolismo , Regulação da Expressão Gênica/efeitos dos fármacos , Células HL-60 , Inibidores de Histona Desacetilases/uso terapêutico , Histona-Lisina N-Metiltransferase/antagonistas & inibidores , Histonas/genética , Ácidos Hidroxâmicos/uso terapêutico , Células K562 , Leucemia/tratamento farmacológico , Leucemia Mieloide Aguda/genética , Piperazinas/uso terapêutico , Regiões Promotoras Genéticas
2.
Experimental & Molecular Medicine ; : e19-2013.
Artigo em Inglês | WPRIM | ID: wpr-147327

RESUMO

New colchicine analogs have been synthesized with the aim of developing stronger potential anticancer activities. Among the analogs, CT20126 has been previously reported to show immunosuppressive activities. Here, we report that CT20126 also shows potential anticancer effects via an unusual mechanism: the modulation of microtubule integrity and cell cycle arrest at the G2/M phase before apoptosis. When we treated COS-7 cells with CT20126 (5 muM), the normal thread-like microtubules were disrupted into tubulin dimers within 10 min and thereafter repolymerized into short, thick filaments. In contrast, cells treated with the same concentration of colchicine exhibited microtubule depolymerization after 20 min and never underwent repolymerization. Furthermore, optical density (OD) analysis (350 nm) with purified tubulin showed that CT20126 had a higher repolymerizing activity than that of Taxol, a potent microtubule-polymerizing agent. These results suggest that the effects of CT20126 on microtubule integrity differ from those of colchicine: the analog first destabilizes microtubules and then stabilizes the disrupted tubulins into short, thick polymers. Furthermore, CT20126 induced a greater level of apoptotic activity in Jurkat T cells than colchicine (assessed by G2/M arrest, caspase-3 activation and cell sorting). At 20 nM, CT20126 induced 47% apoptosis among Jurkat T cells, whereas colchicine induced only 33% apoptosis. Our results suggest that the colchicine analog CT20126 can potently induce apoptosis by disrupting microtubule integrity in a manner that differs from that of colchicine or Taxol.


Assuntos
Animais , Bovinos , Humanos , Acetilação/efeitos dos fármacos , Apoptose/efeitos dos fármacos , Células COS , Caspase 3/metabolismo , Divisão Celular/efeitos dos fármacos , Chlorocebus aethiops , Colchicina/análogos & derivados , Ativação Enzimática/efeitos dos fármacos , Fase G2/efeitos dos fármacos , Células Jurkat , Microtúbulos/metabolismo , Poli(ADP-Ribose) Polimerases/metabolismo , Tubulina (Proteína)/metabolismo , Moduladores de Tubulina/química
3.
Journal of Huazhong University of Science and Technology (Medical Sciences) ; (6): 25-8, 2009.
Artigo em Inglês | WPRIM | ID: wpr-635055

RESUMO

This study investigated the inhibitory effects of curcumin on proliferation of hematological malignant cells in vitro and the anti-tumor mechanism at histone acetylation/histone deacetylation levels. The effects of curcumin and histone deacetylase inhibitor trichostatin A (TSA) on the growth of Raji cells were tested by MTT assay. The expression of acetylated histone-3 (H(3)) in Raji, HL60 and K562 cells, and peripheral blood mononuclear cells (PBMCs) treated with curcumin or TSA was detected by immunohistochemistry and FACS. The results showed curcumin inhibited proliferation of Raji cells significantly in a time- and dose-dependent fashion, while exhibited low toxicity in PBMCs. Curcumin induced up-regulation of the expression of acetylated H(3) dose-dependently in all malignant cell lines tested. In conclusion, curcumin inhibited proliferation of Raji cells selectively, enhanced the level of acetylated (H(3)) in Raji, HL60, and K562 cells, which acted as a histone deacetylase inhibitor like TSA. Furthermore, up-regulation of H(3) acetylation may play an important role in regulating the proliferation of Raji cells.


Assuntos
Acetilação/efeitos dos fármacos , Antineoplásicos/farmacologia , Proliferação de Células/efeitos dos fármacos , Curcumina/farmacologia , Células HL-60 , Inibidores de Histona Desacetilases/farmacologia , Histonas/química , Histonas/efeitos dos fármacos , Células K562 , Triclosan/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA